Hims & Hers在FDA安全和监管警告后停止了其价值49美元的复合司美格鲁肽药丸。 Hims & Hers halted its $49 compounded semaglutide pill after FDA safety and regulatory warnings.

在FDA警告该公司安全性和监管问题后，Hims & Hers已停止提供其价值49美元的复合司美格鲁肽药丸，理由是复合药缺乏FDA批准药物的严格测试和批准。 Hims & Hers has stopped offering its $49 compounded semaglutide pill after the FDA warned the company about safety and regulatory concerns, citing that compounded drugs lack the rigorous testing and approval of FDA-approved medications. 该决定是在加强了对不受标准监管监督的定制重量损失药物的检查之后作出的。 The decision follows increased scrutiny of custom-made weight-loss drugs not subject to standard regulatory oversight. 该公司没有说明是否将重新引进类似产品。 The company did not specify if it will reintroduce a similar product.